Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates

Core Insights - Day One Biopharmaceuticals reported a quarterly loss of $0.05 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.67, and an improvement from a loss of $0.61 per share a year ago [1][12] - The company achieved revenues of $8.19 million for the quarter ended June 2024, exceeding the Zacks Consensus Estimate by 810.22%, compared to zero revenues in the same quarter last year [2] Company Performance - Over the last four quarters, Day One Biopharmaceuticals has surpassed consensus EPS estimates two times [7] - The stock has increased by approximately 5.2% since the beginning of the year, while the S&P 500 has gained 14.5% [8] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.55 on revenues of $19.02 million, and for the current fiscal year, it is -$2.67 on revenues of $28.67 million [10] - The upcoming report is expected to show a quarterly loss of $1.37 per share, reflecting a year-over-year change of -39.8% [11] - The estimate revisions trend for Day One Biopharmaceuticals is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [14] Industry Context - Day One Biopharmaceuticals operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 33% of over 250 Zacks industries [5]